Medical technology and diagnostics companies from North America and the United Kingdom reach India through its regulator, its hospital networks and its state life sciences ecosystems, in that order. Learnova works that path in sequence and builds the operating capability on the Indian side, so that what enters, stays.
Learnova's founder is recognised by a state life sciences foundation in India as a point of contact for exploratory engagement with life sciences companies in Canada, the United States and the United Kingdom.
Healthcare and life sciences is one of the four domains in the Centres of Excellence that three Indian state governments have invited Learnova to create and lead.
Companies holding FDA clearance, CE marking or an equivalent authorisation; hospital and laboratory networks; state life sciences bodies; licensed manufacturers and distributors.
Device classification and the registration or import licence under the Medical Devices Rules, 2017 through CDSCO, with the quality-system and post-market evidence the regulator expects. Then the clinical and health-economic case written for hospital networks, with local validation designed to their standards. Then the procurement pathway, public or private, that turns adoption into purchase orders.
Capacity, throughput, procurement and equipment-maintenance analytics built on the institution's own data, inside its perimeter, with the staff trained to operate and extend the models. Human-in-the-loop by design; no clinical decision is automated.
Deployment of validated point-of-care diagnostics and water-safety testing in primary-care settings, designed for India and for remote communities in Canada, with the training, quality assurance and supply arrangements that keep a programme running after the launch.
Network design, cold-chain and traceability requirements, and regulatory alignment for licensed manufacturers and distributors expanding across India. Learnova advises; the product, the licences and the regulated responsibilities remain with the licensed partners.
A defined cohort of Canadian and American companies holding FDA clearance or CE marking, each with a written case for India, introduced to the state ecosystem through a single point of contact.
A reverse flow: Indian manufacturers, generics and digital-health companies seeking Health Canada pathways and Canadian hospital pilots, introduced to Canada's life sciences clusters and trade commissioner service.
A shared stage: the state's annual life sciences convening as the moment both cohorts meet.
Learnova convenes on its own account and does not speak for the foundation.
India's hospital networks adopt AI-assisted diagnostics on three proofs, in sequence: regulatory standing under the Medical Devices Rules through CDSCO; clinical and health-economic evidence that holds on Indian patient populations and clinical workflows; and a procurement pathway that a public or private network can act on. For companies holding FDA clearance or CE marking, Learnova prepares each file in that order, with local validation designed to the regulator's and the networks' standards, and with patient data remaining in jurisdiction.
The adaptive cognitive training programme for schools, workforces and institutions. Training, not treatment; outcomes measured, not promised.
Population and workplace screening delivered by licensed providers using validated point-of-care diagnostics. Learnova designs the programme, trains the staff and runs the analytics; no test is performed by Learnova.
Programme design and delivery for governments, foundations and employers, covering physical activity, nutrition education and healthy ageing, in partnership with fitness and community networks.
Programme outcomes measured on the institution's own data, inside its perimeter, reported to the institution and owned by it.
Programmes are educational and preventive; they do not diagnose, treat or replace medical care.
This page describes institutional work only. Learnova does not promote prescription products, does not advise on individual treatment and publishes no medical claims. Clinical and regulatory responsibilities rest with the licensed manufacturer, the institution and the regulator.
Let's build capability you keepWhether you are a government, an enterprise or an institution, the conversation starts the same way: what capability do you want to be running, and keeping, five years from now?
